Page 34 - 《中国药房》2024年17期
P. 34

·药学研究·


          苦参醇 F 调节肠道菌群及免疫应答对溃疡性结肠炎小鼠的改善
          作用机制研究
                                Δ


          何旭东 ,宋成竹,倪皓雨,胡蕴铠,李 敏,陈达俊,苏文涛,俞 捷,杨兴鑫(云南中医药大学中药学院,昆明
                *
                                                                               #
          650500)

          中图分类号  R966      文献标志码  A      文章编号  1001-0408(2024)17-2088-08
          DOI  10.6039/j.issn.1001-0408.2024.17.06

          摘   要  目的  探究苦参醇F(KSCF)治疗溃疡性结肠炎(UC)小鼠的作用机制。方法  采用网络药理学与分子对接预测KSCF干
          预 UC 的潜在靶点。将 C57BL/6J 小鼠按体重分为模型组、阳性对照组(柳氮磺胺吡啶,703 mg/kg)、KSCF 组(100 mg/kg )和正常
          组,每组6只;采用饮用葡聚糖硫酸钠溶液的方法建立小鼠UC模型;造模期间灌胃给药,每天1次,连续7 d。末次给药后,对小鼠
          疾病活动指数(DAI)进行评分;测量小鼠结肠长度;观察小鼠结肠组织病理形态学变化;检测小鼠血清中脂多糖(LPS)及结肠中髓
          过氧化物酶(MPO)、一氧化氮(NO)和超氧化物歧化酶(SOD)水平;检测小鼠结肠组织中闭合蛋白(occludin)、紧密连接蛋白 1
         (ZO-1)表达水平;检测小鼠脾脏中CD3 T、CD4 T、CD8 T淋巴细胞比例及CD4 /CD8 值变化;采用16S rDNA测序法分析结肠微生
                                                    +
                                              +
                                                                      +
                                        +
                                                                          +
          物变化。结果  网络药理学结果显示,KSCF可能调节磷脂酰肌醇3激酶/蛋白激酶B、核因子κB(NF-κB)等信号通路治疗UC。分
          子对接结果表明,KSCF与NF-κB p65蛋白结合最稳定。动物实验结果表明,与模型组比较,KSCF组小鼠结肠组织病理形态学特
          征得到改善;DAI评分、血清LPS水平、结肠组织中MPO及NF-κB p65磷酸化和NLRP3蛋白表达水平、脾脏中CD8 T淋巴细胞比
                                                                                                  +
          例显著降低(P<0.05);小鼠体重,结肠组织中SOD水平、occludin和ZO-1表达水平,脾脏中CD3 T、CD4 T淋巴细胞比例及CD4 /                        +
                                                                                    +
                                                                                          +
          CD8 值显著升高(P<0.05);肠道中厚壁菌门、放线菌门、阿克曼氏菌属和乳酸杆菌属丰度增加,变形菌门丰度减少,菌群结构向正
             +
          常组趋近。结论  KSCF通过修复肠道微生态失调、增强免疫应答来抑制结肠炎症反应,改善肠屏障完整性来缓解UC。
          关键词  苦参醇F;溃疡结肠炎;免疫应答;肠道菌群;炎症;氧化应激;16S rDNA测序
          Improvement  mechanism  study  of  kushenol  F  on  ulcerative  colitis  mice  by  regulating  gut  microbiota  and
          immune response
          HE Xudong,SONG Chengzhu,NI Haoyu,HU Yunkai,LI Min,CHEN Dajun,SU Wentao,YU Jie,YANG Xingxin
         (College of Pharmaceutical Science, Yunnan University of Chinese Medicine, Kunming 650500, China)


          ABSTRACT    OBJECTIVE  To  explore  the  action  mechanism  of  kushenol  F (KSCF)  in  treating  ulcerative  colitis (UC)  in  mice.
          METHODS  The  potential  targets  of  KSCF  intervening  in  UC  were  predicted  with  network  pharmacology  and  molecular  docking.
          C57BL/6J  mice  were  randomly  divided  by  body  weight  into  model  group,  positive  control  group (sulfasalazine,  703  mg/kg),
          KSCF  group (100  mg/kg),  and  normal  group,  with  6  mice  per  group.  The  UC  model  of  mice  was  induced  by  dextran  sulfate
          sodium solution. During the modeling period, the mice were given relevant medicine intragastrically, once a day, for 7 consecutive
          days. After  the  last  administration,  the  disease  activity  index (DAI)  of  the  mice  was  scored;  the  length  of  the  mice’s  colon  was
          measured;  pathological  changes  in  the  colon  tissue  of  mice  were  observed;  the  levels  of  lipopolysaccharide (LPS)  in  serum,
          myeloperoxidase (MPO), nitric oxide (NO) and superoxide dismutase (SOD) in the colon were detected in mice; the expression
          levels of occludin and ZO-1 in colon tissue of mice were detected; the proportions of CD3 T, CD4 T, and CD8 T lymphocytes in
                                                                                                +
                                                                               +
                                                                                      +
          the  spleen  and  the  ratio  of  CD4 /CD8   were  detected;  changes  in  colonic  microbiota  were  analyzed  by  16S  rDNA  sequencing.
                                   +
                                        +
          RESULTS  Results  of  network  pharmacology  indicated  that  KSCF  may  treat  UC  by  regulating  signaling  pathways  such  as
                                                              phosphatidylinositol-3  kinase/protein  kinase  B  (PI3K/AKT)
              Δ 基金项目 国家自然科学基金项目(No.82104381,No.82060707);
                                                              and  nuclear  factor  kappa  B (NF- κB).  Molecular  docking
          云南省南药可持续利用研究重点实验室科技人才和平台计划项目
                                                              results  showed  that  KSCF  bound  most  stably  with  NF-κB  p65
         (No.202105AG070012XS2204);云南省教育厅科学研究基金项目
                                                              protein.  Animal  experiment  results  demonstrated  that,
         (No.2024Y385)
             *第一作者 博士研究生。研究方向:中药药效物质分析。E-                     compared   with   the   model   group,   the   pathological
          mail:2758251701@qq.com                              characteristics  of  colon  tissue  in  mice  were  improved  in  KSCF
              # 通信作者 教授,博士生导师。研究方向:中药药效物质分析。                  group.  DAI  scores,  serum  levels  of  LPS,  the  levels  of  MPO,
          E-mail:yxx78945@163.com                             NF-κB  p65  phosphorylation  and  NLRP3  protein  expression  in
          · 2088 ·    China Pharmacy  2024 Vol. 35  No. 17                            中国药房  2024年第35卷第17期
   29   30   31   32   33   34   35   36   37   38   39